Anuh Pharma Ltd

Anuh Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Anuh Pharma Ltd

₹ 235 1.95%
20 Dec 12:03 p.m.
anuhpharma.com BSE: 506260 NSE: ANUHPHR
About

Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]

Key Points

Business Overview:[1][2]
a) APL is a part of the SK Group and is a leading manufacturer of Macrolides and Anti-TB products in India, besides being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids.

b) It is a medium-sized player in the API/bulk drugs industry, manufacturing products such as erythromycin and its salts, and higher macrolides like azithromycin, roxithromycin, pyrazinamide, and chloramphenicol.

c) The company claims to be the largest producer of erythromycin salts in India and among the top five globally. It is also the largest producer of pyrazinamide in the world.

d) APL has marketing partnerships with 350 customers in over 57 countries, including Europe, Mexico, and South Africa.

Website BSE NSE
  • Market Cap ₹ 1,178 Cr.
  • Current Price ₹ 235
  • High / Low ₹ 265 / 146
  • Stock P/E 19.9
  • Book Value ₹ 60.5
  • Dividend Yield 1.02 %
  • ROCE 25.6 %
  • ROE 19.5 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 18.7% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 25.8%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
109 132 129 116 115 139 157 161 150 172 164 138 166
96 120 115 105 102 126 143 148 132 148 145 127 149
Operating Profit 12 12 14 11 13 12 14 14 18 24 19 11 17
OPM % 11% 9% 11% 10% 12% 9% 9% 9% 12% 14% 12% 8% 10%
2 0 1 1 2 2 1 3 2 4 3 4 3
Interest 0 1 -0 0 0 0 0 0 0 0 0 0 0
Depreciation 3 3 3 2 2 2 2 2 2 2 2 2 2
Profit before tax 11 9 12 10 13 12 13 15 18 25 20 12 18
Tax % 22% 16% 26% 24% 23% 23% 25% 24% 23% 24% 22% 22% 17%
9 7 9 7 10 9 10 12 14 19 15 10 15
EPS in Rs 1.72 1.49 1.78 1.46 1.98 1.86 1.92 2.34 2.76 3.81 3.07 1.90 3.00
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
243 266 284 326 206 238 321 307 432 487 527 647 640
225 242 253 289 183 220 291 284 387 439 476 571 569
Operating Profit 18 24 31 38 23 18 30 23 45 47 52 76 71
OPM % 7% 9% 11% 12% 11% 8% 9% 8% 10% 10% 10% 12% 11%
2 4 5 4 8 7 5 4 11 5 6 12 14
Interest 1 1 1 1 1 0 1 1 2 2 1 1 1
Depreciation 2 2 3 2 2 2 2 7 15 12 10 9 8
Profit before tax 18 25 32 38 28 23 32 19 39 39 47 78 75
Tax % 29% 31% 31% 32% 27% 29% 28% 25% 26% 22% 24% 23%
13 18 22 26 20 17 23 14 28 31 36 60 59
EPS in Rs 2.50 3.51 4.39 5.15 4.00 3.30 4.66 2.86 5.68 6.10 7.22 11.99 11.78
Dividend Payout % 40% 37% 27% 24% 31% 42% 29% 48% 26% 29% 28% 21%
Compounded Sales Growth
10 Years: 9%
5 Years: 15%
3 Years: 14%
TTM: 5%
Compounded Profit Growth
10 Years: 12%
5 Years: 19%
3 Years: 32%
TTM: 33%
Stock Price CAGR
10 Years: 15%
5 Years: 29%
3 Years: 31%
1 Year: 56%
Return on Equity
10 Years: 15%
5 Years: 14%
3 Years: 16%
Last Year: 19%

Balance Sheet

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 4 4 4 13 13 13 13 13 25 25 25 25 25
Reserves 71 82 97 107 128 137 152 150 166 189 216 266 278
1 0 0 2 0 2 4 45 14 4 1 3 14
60 77 67 71 48 57 71 119 128 129 163 152 117
Total Liabilities 136 163 168 193 189 209 240 326 333 347 405 446 434
10 12 9 18 17 17 21 84 71 61 53 49 46
CWIP 3 0 0 0 0 6 34 0 0 0 0 0 2
Investments 19 27 43 43 70 66 39 80 31 43 91 97 98
104 124 116 131 101 120 147 163 230 243 261 300 288
Total Assets 136 163 168 193 189 209 240 326 333 347 405 446 434

Cash Flows

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
2 15 19 16 26 2 7 49 -19 29 54 13
4 -5 -12 -5 -20 2 3 -77 52 -8 -43 1
-6 -8 -8 -9 -4 -5 -7 22 -33 -19 -12 -9
Net Cash Flow -0 2 -1 2 2 -1 3 -5 0 2 -2 5

Ratios

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 82 102 88 84 100 109 85 96 90 102 118 107
Inventory Days 43 33 27 35 72 64 64 98 90 77 66 57
Days Payable 86 102 79 77 102 105 89 166 133 117 139 105
Cash Conversion Cycle 39 33 36 42 70 68 61 28 48 62 46 58
Working Capital Days 45 42 43 51 79 83 70 44 68 70 61 68
ROCE % 26% 31% 33% 35% 19% 14% 19% 10% 16% 18% 19% 26%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
70.43% 70.59% 70.59% 70.59% 70.59% 70.59% 70.59% 69.94% 69.91% 69.91% 69.91% 69.91%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.02% 0.02%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.10% 0.00% 0.00% 0.00%
29.56% 29.42% 29.41% 29.40% 29.40% 29.39% 29.40% 30.05% 29.96% 30.05% 30.06% 30.06%
No. of Shareholders 21,12320,74020,45220,47019,96919,42319,06620,51922,23723,49423,91024,048

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls